AbbVie Inc. buy kasimir
Start price
25.09.15
/
50%
€51.70
Target price
26.10.15
€58.63
Performance (%)
-12.75%
End price
26.10.15
€44.65
Summary
This prediction ended on 26.10.15 with a price of €44.65. The prediction for AbbVie Inc. disappointed with a performance of -12.75%. kasimir has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| AbbVie Inc. | -1.958% | -1.958% | 11.928% | 55.888% |
| iShares Core DAX® | 4.094% | 3.543% | 17.404% | 20.326% |
| iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% | 55.365% |
| iShares Nikkei 225® | -1.572% | -4.633% | 15.731% | 2.146% |
| iShares S&P 500 | 1.822% | 0.963% | 30.396% | 45.950% |
Comments by kasimir for this prediction
In the thread AbbVie Inc. diskutieren
Abbvie Inc. kaufen
Mit einem Forward PE von knapp übre 13 und einem Kurs unter 60$ ist Abbvie einen Kauf wert. Stop knapp untre 50$.
(Vom Mitglied beendet)